When he says several studies, I take it to mean different...

When he says several studies, I take it to mean different parameters were studied from the imaging done on patients. I'm pretty sure what he's talking about was presented in the webinar Anteris held a week before that interview, where doctors Meduri, Bapat and Kodali presented imaging results showing the improvement of blood flow provided by the DurAVR compared to 3 competitors and a healthy patient, and the DurAVR matched the healthy patient. They also showed a slide comparing effective orifice areas so maybe that was another parameter studied.

What is unclear to me from that interview is how they got data on 22 patients because the results provided a week earlier were just on 13 Georgian patients. Maybe some of the SAVR patients from the Belgian study were used or perhaps there have been additional patients implanted in Georgia, I don't know. Perhaps Eire or somebody else can shed some light on this stuff.